Online inquiry

IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8557MR)

This product GTTS-WQ8557MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers(CRC), Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8557MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13422MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ3578MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ13116MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ9982MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ15686MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ783MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ12128MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ8098MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW